The 2nd U.S. Circuit Court of Appeals in Manhattan revived more than 500 lawsuits against Kenvue. These claims allege a link between prenatal Tylenol use and the development of autism and ADHD in children.
The ruling overturns a December 2023 decision that previously blocked the cases from trial. Judges determined a lower court improperly dismissed expert witness testimony supporting the plaintiffs.
Kenvue, a consumer health company spun off from Johnson & Johnson, now faces significant legal challenges. The court's decision allows the litigation to proceed without ruling on the scientific validity of the claims.
Kenvue maintains that Tylenol remains safe for use during pregnancy. The company asserts that credible scientific evidence shows no proven link to the developmental disorders.